Compare RNXT & HYPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RNXT | HYPR |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.4M | 83.2M |
| IPO Year | 2021 | 2021 |
| Metric | RNXT | HYPR |
|---|---|---|
| Price | $1.15 | $0.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $7.13 | $2.03 |
| AVG Volume (30 Days) | 547.8K | ★ 875.4K |
| Earning Date | 11-12-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.00 | ★ 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | $1,123,000.00 | ★ $13,563,000.00 |
| Revenue This Year | $244.84 | $49.18 |
| Revenue Next Year | $195.26 | $29.74 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2511.63 | 5.22 |
| 52 Week Low | $0.70 | $0.75 |
| 52 Week High | $2.59 | $2.22 |
| Indicator | RNXT | HYPR |
|---|---|---|
| Relative Strength Index (RSI) | 30.58 | 51.43 |
| Support Level | $0.83 | $0.75 |
| Resistance Level | $1.28 | $1.39 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 4.24 | 35.68 |
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales, which consist of sales from subscriptions of bundled devices, maintenance, and software. The company is in the health technology business with a mission to revolutionize patient care globally through accessible, affordable, clinically relevant artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. The Company operates in one business segment, which includes all activities related to production, supply, service, and commercialization of the Swoop system.